discovering the true signals of disease to power life-changing medicines

90% of drug candidates fail, delaying help for people in need. We’re on a mission to change that.

Learn More
Sequence Bio

drug target discovery powered by the founder effect

Accelerating the deveopment of new medicines relies on discovering better drug targets. 

Getting there means finding the biological components - or true signals - of disease. Sequence Bio was founded on the belief that Newfoundland and Labrador is the best place to look. 


there's nowhere quite like it

Better target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes.

The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.

Icon isolated

founder effect: less biological variation enables more efficient identification of low frequency, high impact variants

Icon electronic records

complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease


better medicines, faster

Our platform is where systems biology and data-driven computation meet to identify the true signals of disease.

See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts. 

partner with sequence bio

Home nlgp 2

newfoundland & labrador genome project

Sequence Bio’s NL Genome Project is researching the genetic makeup of 10,000 volunteering participants in Newfoundland and Labrador. By studying our province’s one-of-a-kind DNA and health information, we hope to discover better, safer medicines and improve how we treat and prevent diseases.

Take me to the NL Genome Project site!

sequence bio


We’re a committed team of more than 50 local and global experts united in our mission to help improve health outcomes with better medicines, faster.

We're hiring, join the team

Chris Gardner

ceo & president

Richard A. Leach PhD

Chief Strategy Officer

Michael S. Phillips PhD

Chief scientific officer

Lynn Healey

Chief Operating & Financial Officer

Dan Brake

Executive Vice President of Technology & Cohort Operations

Jill Van Wart-Hood PhD

vp, business development

Ranjit Randhawa PhD

VP, Research, Data Science & Analytics

Sean Awalt

VP, Partnership Strategy

Joy Buckle MBA MSc

VP, Policy & Planning


scientific advisory board

Dr. Kathy Hudson

board Chair

Dr. Euan Ashley

Stanford medicine

Dr. Pek Lum

auransa inc.


board of directors

Chris Gardner

sequence bio

Mark Dobbin

killick capital

Brendan Paddick

columbus capital

John Phillips

klister credit corp

Sequence Bio is conducting research in Newfoundland and Labrador, and doing so in an ethical way is our first priority. Our research efforts require approval by the Health Research Ethics Board (HREB), and the words “believe,” “expect,” “anticipate,” and similar expressions, among others, generally identify our intent and/or objective to undertake additional research in this province. 

Sequence Bio does not share information about planned research studies until they are approved.